Citation
Godsland, I F., et al. "Insulin Resistance, Secretion, and Metabolism in Users of Oral Contraceptives." The Journal of Clinical Endocrinology and Metabolism, vol. 74, no. 1, 1992, pp. 64-70.
Godsland IF, Walton C, Felton C, et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab. 1992;74(1):64-70.
Godsland, I. F., Walton, C., Felton, C., Proudler, A., Patel, A., & Wynn, V. (1992). Insulin resistance, secretion, and metabolism in users of oral contraceptives. The Journal of Clinical Endocrinology and Metabolism, 74(1), 64-70.
Godsland IF, et al. Insulin Resistance, Secretion, and Metabolism in Users of Oral Contraceptives. J Clin Endocrinol Metab. 1992;74(1):64-70. PubMed PMID: 1530790.
TY - JOUR
T1 - Insulin resistance, secretion, and metabolism in users of oral contraceptives.
AU - Godsland,I F,
AU - Walton,C,
AU - Felton,C,
AU - Proudler,A,
AU - Patel,A,
AU - Wynn,V,
PY - 1992/1/1/pubmed
PY - 1992/1/1/medline
PY - 1992/1/1/entrez
KW - Biology
KW - Carbohydrate Metabolic Effects
KW - Contraception
KW - Contraceptive Agents
KW - Contraceptive Agents, Estrogen
KW - Contraceptive Agents, Female
KW - Contraceptive Agents, Progestin
KW - Contraceptive Methods
KW - Desogestrel
KW - Developed Countries
KW - England
KW - Ethinyl Estradiol
KW - Europe
KW - Examinations And Diagnoses
KW - Family Planning
KW - Glucose Metabolism Effects
KW - Glucose Tolerance Test
KW - Laboratory Examinations And Diagnoses
KW - Laboratory Procedures
KW - Levonorgestrel
KW - Metabolic Effects
KW - Models, Theoretical
KW - Norethindrone
KW - Northern Europe
KW - Oral Contraceptives
KW - Oral Contraceptives, Combined
KW - Oral Contraceptives, Low-dose
KW - Oral Contraceptives, Phasic
KW - Physiology
KW - Progestins, Low-dose
KW - Research Methodology
KW - Research Report
KW - United Kingdom
SP - 64
EP - 70
JF - The Journal of clinical endocrinology and metabolism
JO - J Clin Endocrinol Metab
VL - 74
IS - 1
N2 - Studies of insulin employing the oral glucose tolerance test demonstrate marked differences between the effects of different oral contraceptives, but provide little insight into the underlying disturbances. We investigated the metabolic basis of these disturbances by computer modelling of iv glucose tolerance test glucose, insulin, and C-peptide concentration profiles. Insulin resistance, secretion, and metabolism were evaluated in 296 oral contraceptive users and 95 nonusers. Four estrogen/progestin combinations, with similar estrogen but differing progestin contents, and 1 progestin-only formulation were studied. Effects on iv glucose tolerance test glucose, insulin, and C-peptide concentrations varied according to progestin content, with levonorgestrel-containing combinations having the greatest effect, followed by desogestrel and norethindrone. However, these formulations increased insulin resistance to a similar extent. The progestin-only formulation did not affect insulin resistance. Levonorgestrel combinations increased second phase pancreatic insulin secretion by 60-90%, but did not affect the insulin half-life. The desogestrel combination increased the insulin half-life by 28%, but did not affect insulin secretion. The effects of different combined oral contraceptives on glucose tolerance test glucose, insulin, and C-peptide concentration profiles appears to be due to a combination of estrogen-induced insulin resistance and progestin-associated changes in insulin half-life.
SN - 0021-972X
UR - https://www.unboundmedicine.com/medline/citation/1530790/Insulin_resistance_secretion_and_metabolism_in_users_of_oral_contraceptives_
L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem.74.1.1530790
DB - PRIME
DP - Unbound Medicine
ER -